Bryan Johnson Tracks 249 Biomarkers After Taking a "Heroic Dose" of Psilocybin

In a recent video release, prominent longevity entrepreneur Bryan Johnson detailed the physiological and psychological fallout of consuming a "heroic dose" of magic mushrooms. Known for measuring nearly every facet of his daily existence through his rigorous Blueprint protocol, Johnson turned his relentless quantification toward a substance traditionally seen as the antithesis of sterile, data-driven optimization: psilocybin.

According to Johnson, the single, high-dose psychedelic experience yielded immediate and striking shifts across multiple biological systems, including stress hormones, inflammation markers, brain activity, and, unexpectedly, blood sugar control. While the outcomes caught even his own scientific and medical team off guard, the entrepreneur has emphasized the need for widespread caution, noting that the observations represent an isolated case study rather than a clinically proven protocol.

A Control Freak Meets the Ultimate Wild Card

Bryan Johnson’s entire public-facing longevity project runs on discipline, strict daily precision, and relentless measurement. Psychedelics, by their very nature of altering consciousness and dissolving predictable patterns, initially seemed to stand in direct opposition to that framework.

"My work is about control, doing things with precision, measuring cause and effect," Johnson noted regarding his hesitation. "And psychedelics don’t fit in that framework."

The turning point came when Johnson encountered emerging scientific literature suggesting that psilocybin might promote cellular longevity in laboratory settings, alongside a growing body of mental health data pointing to its therapeutic potential for depression, anxiety, and cognitive rigidity. However, his primary hesitation was not rooted in a fear of the compound itself, but rather in psychological identity. Friends and colleagues warned him about high-profile figures who embarked on intensive psychedelic journeys and subsequently checked out from their worldly responsibilities or lost their professional drive.

Addressing his internal apprehension, Johnson remarked that the fear he experienced prior to dosing was not about mushrooms, but about identity and the potential loss of his carefully cultivated self.

249 Biomarkers and a 5-Gram Dose

To bridge the gap between his analytical world and the unpredictable nature of psychedelics, Johnson opted to track the experience with unprecedented rigor. He administered a five-gram dose of psilocybin under legal, medically supervised conditions. Before swallowing the mushrooms, his team recorded an extensive baseline of 249 distinct biomarkers.

"I don’t think any human before me has measured 249 biomarkers before they took magic mushrooms," Johnson stated, highlighting the obsessive quantification that preceded the session.

His preparation matched the clinical environment: he turned off his phone, secured an early bedtime, and naturally woke up at 5:04 a.m. to begin the structured monitoring process.

Bryan Johnson Took 5g of Psilocybin and His Blood Sugar Control Improved to Better Than 99.8% of Healthy

What It Felt Like: Not Chaos

Despite anticipating severe psychological turbulence from a five-gram dose, Johnson reported an experience characterized by a surprising sense of internal calm and coherence.

"What surprised me the most wasn’t chaos, it was actually the opposite," Johnson said. "A feeling of openness, of connection, a kind of childlike excitement I hadn’t felt in a very long time."

As the trip unfolded, he consciously revisited his primary fear of losing his identity and found that he felt deeply aligned rather than fragmented. Viewing feelings as actionable data, he immediately turned his attention to whether his biology would reflect the perceived internal peace.

What Johnson Says the Data Showed

The aftermath of the session yielded a cascade of physiological readings that Johnson and his team documented across several key health categories.

Stress hormones exhibited a dramatic, transient spike followed by a pronounced calming effect. Cortisol levels surged to between three and eight times his normal midday baseline for roughly three hours immediately following ingestion. However, by the evening, those levels had normalized. Five days post-dose, his morning cortisol had dropped by 42 percent, while DHEA, another key adrenal marker, fell by 45 percent. Johnson compared this transition to a choppy sea suddenly turning to glass, tying it to the colloquial "afterglow" reported by many psychedelic users.

Brain activity, mapped using Kernel Flow—the neuroimaging hardware system Johnson spent seven years developing—revealed significant shifts in neural architecture. His default mode network, often described as the brain’s command center for the ego and self-referential thought, went quiet. Simultaneously, sensory, auditory, and language regions of the brain began communicating with heightened cross-talk, a state of increased entropy. Scans taken three weeks after the initial dose showed lingering baseline changes, which appeared to be reinforced by a subsequent second dose.

Blood sugar regulation presented the most unexpected finding of the experiment. Analyzing continuous glucose monitor data from three days before and three days after the first dose, Johnson reported a marked improvement in glycemic control, placing his estimated metrics in an elite tier. However, context remains critical: this figure represents a short-term estimate drawn from a narrow three-day window rather than a verified, lab-tested long-term average like a standard HbA1c test. Comparing such acute fluctuations to established pharmaceutical interventions like metformin requires far more extensive, controlled clinical validation.

Inflammation and gut microbiome markers also shifted during the monitoring period. His high-sensitivity C-reactive protein (hs-CRP), a systemic marker of low-grade inflammation, started at a low 0.23, dropped below the test’s detection limit of 0.15 five days after the first dose, and remained suppressed following the second dose. Concurrently, analysis of his gut microbiome showed a reduction in bacterial species associated with stress, anxiety, and insulin resistance, alongside the emergence of a new bacterial species whose long-term health implications remain entirely unknown.

Finally, thermal imaging captured a distinct physiological shift, with his core body temperature rising by 1.5 to 2 degrees Fahrenheit during the height of the experience. This inward movement of heat pointed to deep autonomic nervous system activation.

Bryan Johnson Took 5g of Psilocybin and His Blood Sugar Control Improved to Better Than 99.8% of Healthy

What One Person’s Data Can’t Tell You

Despite the volume of data collected, Johnson maintains a measured and cautious perspective regarding the broader scientific implications of his experiment.

"These are first in human observations, which needs replication," Johnson acknowledged. "Both the magnitude and the durability need further study."

Independent scientific evaluation points out several critical limitations. The data stems from a single participant operating without a control group or a placebo mechanism. Consequently, it is impossible to definitively separate cause and effect from normal biological variation, coincidence, or the acute stress of participating in a high-stakes, livestreamed scientific stunt. Furthermore, because Johnson’s daily health metrics are already heavily optimized through strict diet, exercise, and sleep protocols, his baseline inflammation was already exceptionally low, meaning the observed changes occurred at the margins of what standard tests can reliably detect.

Additional longevity metrics, such as telomere length and epigenetic age estimations, remain pending. Because these findings were released directly by Johnson’s own team rather than through peer-reviewed, independent clinical trials, categorizing psilocybin as a validated longevity therapy remains premature.

Johnson was explicitly clear that his personal experiment should not be interpreted as a directive for others. He reiterated that the session occurred under strict medical supervision and within a legal framework, emphasizing that the results do not constitute an endorsement or a recommendation for self-experimentation. Psilocybin remains a controlled substance in many jurisdictions, and high-dose psychedelic experiences carry substantial psychological and physical risks, particularly for individuals with personal or family histories of psychotic disorders.

The entrepreneur concluded his public disclosure by connecting the experiment to his deeply personal history with severe depression, recalling periods where he suffered from debilitating despair and suicidal ideation.

"Don’t Die didn’t start as a mission to extend life," Johnson reflected. "It started as a way to stay alive."

For individuals currently facing severe mental health struggles, health professionals advise reaching out to licensed mental health practitioners or local crisis support lines for assistance.

More From Author

Josh Hokit and Jon Jones Trade Explosive Barbs in Heated Online Exchange Following UFC 334

The Final Ten: The U.S. States That Have Never Hosted an Official UFC Event

Leave a Reply

Your email address will not be published. Required fields are marked *